

## Special Issue

# Basic Virological Aspects of SARS-CoV-2

### Message from the Guest Editors

This new information required about SARS-CoV-2 needed to be focused on understanding the physiopathology of the COVID-19 disease, identifying biomarkers, and designing a vaccine and treatments. The scope of this Special Issue is to gather information about the basic virology aspects of SARS-CoV-2 and their impact on the design of vaccines and/or drugs. Further, the basic virology aspect can be focused on to understand the physiopathology of COVID-19 disease. Before the COVID-19 pandemic, SARS viruses had a relative slow evolution rate. However, globalization, unequal strategies to control or mitigate the pandemic around the world, and the generation of several vaccines increased the evolution rate. This evolution, centered in the scope of the immune system, had a great impact on the persistence of the pandemic and a critical decrease in vaccines' effectiveness. Therefore, understanding the basic virological aspect of this virus through high-quality information will allow us to generate better strategies against this virus.

---

### Guest Editors

Dr. Andreu Comas-Garcia

Dr. Sofia Bernal-Silva

Prof. Dr. S. Louise Cosby

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/151004](https://mdpi.com/si/151004)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).